Polymorphisms in signal transducer and activator of transcription 3 and lung function in asthma

被引:40
作者
Litonjua, AA
Tantisira, KG
Lake, S
Lazarus, R
Richter, BG
Gabriel, S
Silverman, ES
Weiss, ST
机构
[1] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA
[2] Beth Israel Deaconess Med Ctr, Div Pulm & Crit Care Med, Boston, MA 02215 USA
[3] Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Boston, MA 02115 USA
[5] MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA
来源
RESPIRATORY RESEARCH | 2005年 / 6卷 / 1期
关键词
D O I
10.1186/1465-9921-6-52
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Identifying genetic determinants for lung function is important in providing insight into the pathophysiology of asthma. Signal transducer and activator of transcription 3 is a transcription factor latent in the cytoplasm; the gene (STAT3) is activated by a wide range of cytokines, and may play a role in lung development and asthma pathogenesis. Methods: We genotyped six single nucleotide polymorphisms (SNPs) in the STAT3 gene in a cohort of 401 Caucasian adult asthmatics. The associations between each SNP and forced expiratory volume in 1 second (FEV1), as a percent of predicted, at the baseline exam were tested using multiple linear regression models. Longitudinal analyses involving repeated measures of FEV1 were conducted with mixed linear models. Haplotype analyses were conducted using imputed haplotypes. We completed a second association study by genotyping the same six polymorphisms in a cohort of 652 Caucasian children with asthma. Results: We found that three polymorphisms were significantly associated with baseline FEV1: homozygotes for the minor alleles of each polymorphism had lower FEV1 than homozygotes for the major alleles. Moreover, these associations persisted when we performed an analysis on repeated measures of FEV1 over 8 weeks. A haplotypic analysis based on the six polymorphisms indicated that two haplotypes were associated with baseline FEV1. Among the childhood asthmatics, one polymorphism was associated with both baseline FEV1 and the repeated measures of FEV1 over 4 years. Conclusion: Our results indicate that genetic variants in STAT3, independent of asthma treatment, are determinants of FEV1 in both adults and children with asthma, and suggest that STAT3 may participate in inflammatory pathways that have an impact on level of lung function.
引用
收藏
页数:10
相关论文
共 33 条
[1]   Controlling the false discovery rate in behavior genetics research [J].
Benjamini, Y ;
Drai, D ;
Elmer, G ;
Kafkafi, N ;
Golani, I .
BEHAVIOURAL BRAIN RESEARCH, 2001, 125 (1-2) :279-284
[2]  
Benjamini Y, 1999, DISTRIBUTION FREE MU
[3]   Stat3 as an oncogene [J].
Bromberg, JF ;
Wrzeszczynska, MH ;
Devgan, G ;
Zhao, YX ;
Pestell, RG ;
Albanese, C ;
Darnell, JE .
CELL, 1999, 98 (03) :295-303
[4]   STAT proteins:: From normal control of cellular events to tumorigenesis [J].
Calò, V ;
Migliavacca, M ;
Bazan, V ;
Macaluso, M ;
Buscemi, M ;
Gebbia, N ;
Russo, A .
JOURNAL OF CELLULAR PHYSIOLOGY, 2003, 197 (02) :157-168
[5]   Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium [J].
Carlson, CS ;
Eberle, MA ;
Rieder, MJ ;
Yi, Q ;
Kruglyak, L ;
Nickerson, DA .
AMERICAN JOURNAL OF HUMAN GENETICS, 2004, 74 (01) :106-120
[6]   Novel anti-inflammatory effects of the inhaled corticosteroid fluticasone propionate during lung myofibroblastic differentiation [J].
Cazes, E ;
Giron-Michel, J ;
Baouz, S ;
Doucet, C ;
Cagnoni, F ;
Oddera, S ;
Körner, M ;
Dasic, G ;
Testi, R ;
Azzarone, B ;
Canonica, GW .
JOURNAL OF IMMUNOLOGY, 2001, 167 (09) :5329-5337
[7]   Application of an algorithm for the diagnosis of asthma in Chinese families - Limitations and alternatives for the phenotypic assessment of asthma in family-based genetic studies [J].
Celedon, JC ;
Silverman, EK ;
Weiss, ST ;
Wang, BY ;
Fang, ZH ;
Xu, XP .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (05) :1679-1684
[8]  
Chapman RS, 2000, ADV EXP MED BIOL, V480, P129
[9]  
Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91
[10]  
Doucet C, 2002, EUR J IMMUNOL, V32, P2437, DOI 10.1002/1521-4141(200209)32:9<2437::AID-IMMU2437>3.0.CO